NDC 71858-0010-04 - Tirosint
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 71858-0010
- Requested NDC
- 71858-0010-04
- Package NDCs from labels
- 71858-0010-4, 71858-0010-1, 71858-0010-2, 71858-0010-04
- Manufacturer
- IBSA Pharma Inc.
- Effective date
- 2026-03-25
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Tirosint - IBSA Pharma Inc. | IBSA Pharma Inc. | 2026-03-25 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 71858-0010-1 | Tirosint | 1 in 1 CARTON | CAPSULE | 1 | 13 | |
| 71858-0010-1 | Tirosint | 10 in 1 BLISTER PACK | CAPSULE | 10 | 13 | |
| 71858-0010-2 | Tirosint | 3 in 1 CARTON | CAPSULE | 3 | 13 | |
| 71858-0010-2 | Tirosint | 10 in 1 BLISTER PACK | CAPSULE | 10 | 13 | |
| 71858-0010-4 | Tirosint | 10 in 1 BLISTER PACK | CAPSULE | 10 | 13 | |
| 71858-0010-4 | Tirosint | 3 in 1 CARTON | CAPSULE | 3 | 13 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 71858-0010 | TIROSINT (LEVOTHYROXINE SODIUM) CAPSULE [IBSA PHARMA INC.] | 11 | Current NDC, Legacy NDC, 6 package rows | 20241027_7a7ade79-0165-4e31-b84e-667416c00c7e.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 71858-0010-4 | EA - Each | 71858-0010 | 8f761cf5-7112-4857-b7b7-8b5c293cc319 | 1 | 2018-12-13 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Optase | GLYCERIN | Scope Health Inc | 376e0289-28e9-e87f-e063-6294a90a3b04 | 2026-01-30 | Warnings | PDC6A3C0OX |
| Optase | GLYCERIN | Scope Health Inc | 10c3e31d-779d-8ff6-e063-6294a90acd39 | 2026-01-30 | Warnings | PDC6A3C0OX |
| Optase | GLYCERIN | Scope Health Inc | 9e96976b-2990-79e0-e053-2995a90a0f29 | 2026-01-30 | Warnings | PDC6A3C0OX |
| Optase | GLYCERIN | Scope Health Inc | d81c1a4f-87b0-ee8c-e053-2995a90af9e5 | 2026-01-30 | Warnings | PDC6A3C0OX |
| Optase | GLYCERIN | Scope Health Inc | f452a2c4-c869-7bf5-e053-2995a90ac1a0 | 2026-01-30 | Warnings | PDC6A3C0OX |
| Regener-Eyes Ophthalmic Solution LITE XL | GLYCERIN OPHTHALMIC SOLUTION | M & M PRODUCTS, L.L.C. | 47ab9609-4291-30b2-e063-6394a90a421e | 2026-01-29 | Warnings | PDC6A3C0OX |
| Regener-Eyes Ophthalmic Solution PROFESSIONAL STRENGTH XL | GLYCERIN OPHTHALMIC SOLUTION | M & M PRODUCTS, L.L.C. | 48d6dc98-66e8-b499-e063-6394a90ae935 | 2026-01-29 | Warnings | PDC6A3C0OX |
| Optase | GLYCERIN | Scope Health Inc | 86c14327-ffc7-806e-e053-2991aa0aaf92 | 2026-01-29 | Warnings | PDC6A3C0OX |
| Regener-Eyes Ophthalmic Solution PROFESSIONAL | GLYCERIN OPHTHALMIC SOLUTION | M & M PRODUCTS, LLC | 49771efa-6682-51d0-e063-6294a90a18a5 | 2026-01-28 | Warnings | PDC6A3C0OX |
| Regener-Eyes Ophthalmic Solution LITE | GLYCERIN OPHTHALMIC SOLUTION | M & M PRODUCTS, LLC | 497763ee-dc70-bb48-e063-6294a90afb3d | 2026-01-28 | Warnings | PDC6A3C0OX |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Northwind Health Company, LLC | ffc34bc6-5de5-addb-e053-6294a90a25be | 2026-01-26 | Boxed warning, Warnings, Adverse reactions | 9J765S329G |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | NuCare Pharmaceuticals, Inc. | 49136b34-1bc1-ec4e-e063-6394a90ac9dd | 2026-01-23 | Boxed warning, Warnings, Adverse reactions | 9J765S329G |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | f2bed4e7-86e9-430e-80d9-7bd7cfcf9bf5 | 2026-01-23 | Boxed warning, Warnings, Adverse reactions | 9J765S329G |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | 8f7dc71e-4a48-4ba5-945b-f340ff51636e | 2026-01-23 | Boxed warning, Warnings, Adverse reactions | 9J765S329G |
| INSULIN DILUTING MEDIUM FOR Kirsty | WATER | Biocon Biologics Inc. | 3db1d482-7e1f-aec6-79ef-3f305b4d8277 | 2026-01-20 | Warnings, Adverse reactions | 059QF0KO0R |
| Levothyroxine sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | 36af0286-e447-4098-b3f2-772debd58667 | 2026-01-20 | Boxed warning, Warnings, Adverse reactions | 9J765S329G |
| Levothyroxine sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | e8142948-2bde-4f4b-931e-da43e91f2d59 | 2026-01-20 | Boxed warning, Warnings, Adverse reactions | 9J765S329G |
| Levothyroxine sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | d29bc0fd-5587-4a70-a505-f5aee1f115a6 | 2026-01-20 | Boxed warning, Warnings, Adverse reactions | 9J765S329G |
| Levothyroxine sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | d5b11dac-1acd-4aa2-b837-e3b90d4f6922 | 2026-01-20 | Boxed warning, Warnings, Adverse reactions | 9J765S329G |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Northwind Health Company, LLC | f6c92836-95e1-1402-e053-6394a90a2f5e | 2026-01-19 | Boxed warning, Warnings, Adverse reactions | 9J765S329G |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.